{"id":"W2910644531","doi":"10.1016/j.ejca.2018.12.006","title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Sunitinib; Medicine; Toxicity; Renal cell carcinoma; Dosing; Clinical endpoint; Internal medicine; Clinical trial; Phases of clinical research; Oncology; Adverse effect; Urology; Confidence interval; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003734595,0.001575159,0.003190763,0.0006616177,0.0003864889,0.001039573,0.0009705311,0.001977623,0.003490323],"category_scores_gemma":[0.001789788,0.0006268254,0.001789027,0.0004975608,0.001011913,0.0009227058,0.0004486747,0.002624009,0.0005497579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001122832,"about_ca_system_score_gemma":0.001547956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004440759,"about_ca_topic_score_gemma":0.0009238031,"domain_scores_codex":[0.9989848,0.0005328019,0.00005709734,0.0002028373,0.0001034633,0.0001190846],"domain_scores_gemma":[0.9986885,0.0003066944,0.0003781969,0.000136187,0.00008198894,0.0004083636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8885351,0.04627445,0.002807043,0.000881651,0.001665209,0.0001355879,0.000178793,0.00331826,0.01315936,0.0001031163,0.0007674581,0.0421739],"study_design_scores_gemma":[0.7396612,0.2536708,0.00367964,0.00001987519,0.0003295228,0.0001111638,0.00001275761,0.001033632,0.0009980131,0.00009243797,0.0003704594,0.00002045933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957349,0.001263501,0.0003146761,0.0001532952,0.00006605122,0.001718654,0.0002732447,0.00004397145,0.0004318016],"genre_scores_gemma":[0.9923335,0.001086077,0.00148357,0.0002646424,0.0001634224,0.003038187,0.0007382354,0.00001726125,0.0008751613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003734595,"threshold_uncertainty_score":0.01975065,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09894425372658124,"score_gpt":0.3957872506001386,"score_spread":0.2968429968735574,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}